Singapore's biotech sector has grown materially over the past decade. The number of Singapore-based biotech startups has grown from fewer than ten in 2012 to around 65 in 2023 and is expected to increase by more than 60 per cent between 2022 and 2032, according to the Economic Development Board. Biopolis, the research cluster in one-north, houses more than 50 biomedical science organisations. The Singapore government's RIE2030 plan commits S$37 billion to science and technology development, with health and biomedical sciences as a central pillar.
Behind the headline investment figures is a sector with a risk profile that most general insurance intermediaries are not equipped to assess. A biotech company's activities can span early-stage basic research, preclinical animal studies, investigational new drug applications, Phase I to Phase III human clinical trials, regulatory submissions, and in some cases commercial manufacture and distribution of an approved product, all within the same organisation and sometimes across multiple jurisdictions simultaneously.
The insurance programme that a biotech company needs reflects that complexity. This post explains what it should cover and why standard commercial policies fall short.
What makes biotech insurance different from standard business insurance
Most commercial insurance products are written for businesses that operate within a reasonably predictable risk boundary. A professional services firm gives advice. A manufacturer makes a product. A tech company develops software. The liability that arises from each of these activities is well-understood and the policy wordings are designed to address it.
A biotech company does not fit neatly into any of these categories. It may simultaneously be developing a novel biological therapy that has never been administered to a human, running a clinical trial on a patient population that carries significant medical risk, generating and holding proprietary intellectual property that represents years of research value, and providing scientific services to a commercial client under a contract that specifies deliverable outcomes and performance standards.
Each of these activities creates a different category of liability, and standard commercial policies address none of them well.
Standard product liability policies exclude investigational products that have not yet received regulatory approval. A biotech company whose lead asset is in Phase II trials holds no commercial product. Its most significant liability, the risk that a trial participant is harmed by the investigational therapy, is not addressed by a standard product liability policy.
Standard professional indemnity policies are written for advice-based professional services. A biotech company providing contract research services, running a trial, or conducting laboratory analysis is providing professional services, but the output is scientific rather than advisory and the liability that arises from an error is connected to physical outcomes rather than financial advice. Standard PI wordings may exclude bodily injury, which is precisely the category of harm most relevant to clinical and laboratory work.
Standard public liability policies cover accidental bodily injury and property damage on the premises. They do not address the product, clinical trial, or professional service dimensions of a biotech company's activities.
The result is that a biotech company which arranges standard commercial cover may hold a set of policies that collectively cover almost none of its material risk.
The insurance programme a Singapore biotech company needs
Products and services liability. A specialist life sciences policy combines product liability and professional services liability in a single wording, specifically designed for organisations where the boundary between a product and a service is blurred. For a biotech company, this combined wording addresses liability arising from both the physical outputs of the organisation, biological agents, devices, diagnostics, formulations, and the professional services it provides alongside or instead of those physical outputs, contract research, laboratory analysis, scientific consulting, and regulatory advisory.
The combination in a single wording is operationally important. It prevents the situation where a claim arises from an activity that sits at the boundary between a product and a service, and the product policy points to the professional services exclusion while the PI policy points to the bodily injury exclusion, leaving the claim without a responding policy.
Clinical trials liability. For a biotech company conducting human clinical trials in Singapore or internationally, clinical trials insurance is both a practical necessity and in Singapore a regulatory requirement. The Health Sciences Authority requires sponsors of clinical trials involving human subjects to hold appropriate clinical trial insurance before the first participant is enrolled.
Clinical trials liability has a specific feature that distinguishes it from standard liability insurance: no-fault compensation. A trial participant who suffers an adverse event as a result of the investigational product may be entitled to compensation even where no negligence on the sponsor's part can be established. This reflects the ethical obligation to participants who voluntarily take on risk in the advancement of scientific knowledge. Standard liability insurance requires fault to be established before a claim is paid. Clinical trials insurance does not.
For a biotech company running trials across multiple jurisdictions, the interaction between the local compulsory insurance requirement in each jurisdiction and the master programme covering the global trial is a structuring question that requires specific expertise. Where local compulsory limits are lower than the actual settlement reached, a master policy with a difference-in-limits provision allows the global programme to respond to the shortfall.
Professional indemnity. A biotech company that provides scientific services to external clients, whether contract research, regulatory consulting, laboratory testing, or data analysis, has a professional services liability exposure independent of any clinical trial. An error in a regulatory submission that causes a client's application to fail, a laboratory analysis that produces incorrect results on which a client makes a significant business decision, or a research protocol that is found to be flawed are all professional indemnity claims.
For a biotech company that is both developing its own pipeline and providing services to external clients, the PI cover needs to address both dimensions. The scope of covered services should be confirmed at inception and updated as the company's service offering evolves.
Cyber insurance. A biotech company holds data that is valuable, sensitive, and in some cases legally protected in multiple jurisdictions simultaneously. Clinical trial data from human participants is personal health data subject to the PDPA in Singapore, the GDPR where European participants are enrolled, and the equivalent regulations in each other jurisdiction. Proprietary research data representing years of scientific work and potentially significant intellectual value is held on the company's systems. Regulatory submission packages for novel therapies are commercially sensitive and in some cases subject to competitive intelligence risk.
A ransomware attack that encrypts a biotech company's data systems creates multiple simultaneous consequences: the loss of access to research data during the response period, potential exposure of trial participant data triggering notification obligations in multiple jurisdictions, and potential exposure of proprietary research to external parties. The cost of responding to a serious cyber incident in a biotech company, including forensic investigation, legal advice across multiple jurisdictions, participant notification, and data restoration, can be significant relative to the size of the organisation.
Property with life sciences extensions. The standard property policy is not designed for laboratory and research environments. A biotech company's premises may contain specialist research equipment with long procurement lead times, controlled environment storage for biological materials, research animals used in preclinical studies, and experimental outputs representing accumulated scientific value that cannot simply be purchased for replacement. Life sciences property extensions address contamination incidents, radioactive contamination, loss of research income where a contamination event disrupts a programme, and cover for scientific animals.
The clinical stage question
The appropriate insurance structure for a biotech company depends in part on where the company sits in its development lifecycle. The risk profile at preclinical stage, where work is confined to laboratory and animal studies and no human subjects are involved, is materially different from the risk profile at Phase II, where the investigational product is being administered to a patient population under a trial protocol.
For a preclinical-stage biotech, the primary insurance priorities are professional indemnity for any contract research services provided, property cover for the laboratory environment, and cyber cover for research data. Clinical trials liability is not yet relevant.
For a company entering Phase I, clinical trials liability becomes a primary requirement. The design of the Phase I protocol, the eligibility criteria for participants, the dose escalation schedule, and the safety monitoring arrangements all affect the underwriting assessment. Early engagement with a specialist underwriter is more productive than a last-minute application before the first participant is enrolled.
For a company with a product approaching regulatory approval or commercialisation, product liability cover for the commercial product becomes relevant alongside the clinical trial programme that may still be running for other indications.
What Singapore specifically requires
Singapore is an active clinical trial jurisdiction with a regulatory framework administered by the Health Sciences Authority under the Health Products Act. Singapore was the first regulator to receive the highest maturity level in the World Health Organization's classification of regulatory authorities for medical products, a standing that makes Singapore an attractive anchor jurisdiction for multinational trial sponsors in Asia.
For any biotech company conducting a clinical trial involving human subjects in Singapore, HSA requires evidence of appropriate clinical trial insurance as a condition of trial approval. The policy must cover participant injury including no-fault compensation and must be in place before enrolment begins.
For biotech companies headquartered in Singapore with trial sites in multiple Asian jurisdictions, coordinating the local compulsory requirements across those jurisdictions within a single master programme is a practical structuring challenge that is best addressed at the design stage of the trial programme, not at the point of a regulatory submission.
You can read more about our approach to life sciences insurance in our overview post for the sector and about our professional indemnity cover and product liability cover on the products page.
If you are a biotech company at any stage of development and would like to understand how your current insurance arrangements sit against your actual activities and liability exposure, we would be glad to work through it with you.
This article provides general information only. It is not insurance advice. Singapore biotech sector growth statistics sourced from the Economic Development Board. HSA clinical trial insurance requirements sourced from the Health Sciences Authority and the Health Products Act. RIE2030 investment figures sourced from the National Research Foundation Singapore. Policy availability, terms, conditions, and exclusions vary by insurer and product, and cover is subject to the full policy wording. Please contact TZY CO for advice on your specific situation.